Thera-SAbDab

MOGAMULIZUMAB

>   Structural Summary
TherapeuticMogamulizumab
TargetCCR4
Heavy ChainEVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
Light ChainDVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedAmgen, Bristol-Myers Squibb, Kagoshima University Dental School, Kyowa Hakko, Kyowa Hakko Kirin, Ono Pharmaceutical
Conditions ApprovedAdult T-cell leukaemia-lymphoma, Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Mycosis fungoides, Sezary syndrome
Conditions ActiveSpinal cord disorders, Solid tumours
Conditions DiscontinuedNon-small cell lung cancer, Asthma, Hypersensitivity
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]